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EDITORIAL
Population Screening With Coronary Computed 
Tomography Angiography and the Prevention of 
Coronary Events
Kuan Ken Lee, MBChB; Ryan Wereski, MBChB; Michelle C. Williams, MBChB, PhD; Nicholas L. Mills , MBChB, PhD 
Coronary heart disease is the most common cause of death worldwide and is responsible for the death of approximately 9 million persons each year.1 This 
condition often presents with an unheralded acute coro-
nary event, such as a myocardial infarction or a sudden 
cardiac death, but coronary atherosclerosis has invariably 
been present for years before the onset of symptoms. 
Despite having effective, low-cost treatments that pre-
vent acute coronary events, our current approach to pre-
vention is based on population estimates of risk rather 
than on diagnostic testing with coronary imaging. Proba-
bilistic risk scores are imprecise and may result in both 
unnecessary life-long therapies in those without disease 
and failure to initiate treatment in those at greatest risk. 
Furthermore, although the use of probabilistic risk scores 
is widespread, their effectiveness has not been validated 
by clinical trial evidence.2
Article, see p 916
In recent years, the use of invasive and noninvasive 
coronary imaging has become the standard of care for 
persons with symptomatic coronary artery disease.3 In 
particular, the use of coronary computed tomography 
angiography (CCTA) has been shown to improve diagno-
sis and change treatment, potentially leading to reduced 
risk of future myocardial infarction.4,5 Modern scanners 
and imaging protocols enable rapid and accurate quan-
tification of coronary atherosclerosis at a low radiation 
dose and raise the possibility that CCTA could play a 
wider role in the targeting of preventative therapies 
through population screening.
To inform the design of future strategies to prevent 
coronary heart disease, an essential first step is to define 
the true prevalence of coronary atherosclerosis in the 
general population. Previous estimates have been based 
on postmortem evidence; small, selected populations; or 
coronary artery calcification (CAC), an incomplete mea-
sure of disease. In this context, the findings of the SCA-
PIS trial (Swedish Cardiopulmonary Bioimage Study) are 
particularly important.6
The SCAPIS investigators recruited 30 154 men 
and women 50 to 64 years of age who were randomly 
selected from the population to undergo a comprehen-
sive assessment including the measurement of risk fac-
tors and CCTA imaging.7 Their aim was to determine 
the prevalence and burden of coronary atherosclerosis 
and its association with risk scores and CAC. In this first 
article describing results from SCAPIS, Bergström et 
al report findings from 25 182 persons without a previ-
ous myocardial infarction or coronary intervention who 
had a valid measurement of CAC and an interpretable 
CCTA (Figure). They report several important observa-
tions. First, silent coronary atherosclerosis is common in 
the general population with 4 of 10 persons having any 
atheroma. The prevalence was 2-fold higher in men than 
in women and increased with age. Coronary atheroscle-
rosis was considered significant (>50% stenoses) in 1 
of 20 persons, and severe involving the left main stem, 
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in 1 of 50 persons. Second, the onset of coronary ath-
erosclerosis was delayed by 10 years in women, but the 
distribution and pattern of disease was identical in both 
sexes. Third, although there were associations between 
coronary atherosclerosis, risk scores, and CAC, important 
subgroups were identified where atheroma burden was 
not accurately represented by either risk scores or CAC.
Do estimates of the prevalence of coronary athero-
sclerosis in the SCAPIS cohort reflect the wider popula-
tion? The prevalence identified by CCTA in SCAPIS was 
slightly higher than previous estimates that have relied 
on CAC alone,8 as is to be expected given that CCTA 
provides a more detailed assessment. It is plausible that 
selection bias could overestimate prevalence, but the 
investigators ensured that their findings were repre-
sentative by identifying potential participants at random 
using a population census. They enrolled an impressive 
50.3% of those invited to participate with no differences 
in enrollment by age or sex. Furthermore, they used a 
national sociodemographic register and inverse prob-
ability for participation weighting to adjust for any differ-
ences in the recruited population from the age-matched 
population in Sweden, and the prevalence of coronary 
atherosclerosis was largely unchanged.
Sex-based differences in the pattern of coronary 
artery disease in symptomatic persons are well estab-
lished,9,10 but these observations are susceptible to 
selection bias with women less commonly enrolled or 
referred for coronary imaging. In support of this con-
cern, in patients with ST-segment–elevation myocardial 
infarction, where coronary angiography is ubiquitous and 
decisions are made before hospitalization, the pattern of 
disease and plaque characteristics are identical in men 
and women.11 Although Bergström et al demonstrate that 
the prevalence of coronary atherosclerosis was 2-fold 
higher in men than in women in middle age, the distribu-
tion and burden of disease were identical, but the onset 
was delayed by 10 years in women. Thus, Bergström et 
al provide further support for the theory that coronary 
atherosclerosis is the same in women and men but pres-
ents at a later stage in women. The reasons for this are 
poorly understood but are likely to reflect the protective 
or harmful effects of sex hormones on atherosclerosis or 
other yet unknown factors.
Could CCTA improve the targeting of preventative 
therapies compared with probabilistic risk scores and 
CAC scoring in the general population? Although risk 
scores have been externally validated in large cohorts 
and perform well at predicting coronary events at a popu-
lation level,12 there are inherent limitations when applying 
these in individuals. They are well known to systemati-
cally overestimate and underestimate risk in certain eth-
nic groups, by socioeconomic status, and in those with 
comorbidities such as chronic inflammatory diseases.13,14 
Furthermore, many patients are classified as borderline 
or intermediate risk, in whom the benefit of preventative 
therapy is uncertain.
The SCAPIS investigators observed a good correla-
tion between the prevalence of coronary atherosclerosis 
and risk categories using the Systematic Coronary Risk 
Estimation and the Pooled Cohort Equation.7 Those par-
ticipants classified as high risk had a 2.1-fold (95% CI, 
2.0–2.2) and 2.9-fold (95% CI, 2.8–3.0) higher preva-
lence of coronary atherosclerosis than did those classi-
fied as low risk by Systematic Coronary Risk Estimation 
and the Pooled Cohort Equation, respectively. However, in 
Figure. Prevalence of coronary artery disease in middle-aged men and women without previous myocardial infarction or 
coronary intervention.
SCAPIS (Swedish Cardiopulmonary Bioimage Study) enrolled 25 182 men and women 50 to 64 years of age without previous infarction or 
coronary intervention randomly selected from the general population. Coronary computed tomography angiography identified any coronary 
atherosclerosis in 42% (Left), which was significant with ≥50% stenoses or a coronary artery calcification (CAC) score >400 in 5.2% and 
3.5%, respectively (Middle), with the prevalence of both increasing by age and was twice as common in men as in women. Although the onset 
of coronary atherosclerosis was delayed by 10 years in women, the distribution and pattern of disease were similar in both sexes (Right). CA 
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those classified as low risk by both scores, as many as 1 
of 3 men and 1 of 4 women were found to have coronary 
atherosclerosis. Furthermore, in women, the prevalence 
of coronary atherosclerosis was similar whether they 
were classified as moderate or high risk by the System-
atic Coronary Risk Estimation, suggesting that discrimina-
tion in those who are higher risk could also be improved. 
Although CAC scoring is recommended by guidelines in 
persons who are borderline or intermediate risk using the 
Pooled Cohort Equation,12 5.5% and 81.9% of partici-
pants with zero or very low1–10 CAC scores had evidence 
of atherosclerosis on CCTA. For those who use CAC 
scoring in their practice, SCAPIS also provides insights 
into the prevalence of severe coronary atherosclerosis 
stratified by CAC score. In asymptomatic persons with a 
high CAC score (>400), it was remarkable that 1 of 5 had 
≥50% stenosis in the left main stem, proximal left anterior 
descending artery, or all 3 coronary arteries.
There are several potential explanations for these 
discordant findings. Probabilistic risk scores were devel-
oped in older populations and designed to predict myo-
cardial infarction, stroke, or cardiovascular death at 10 
years. In contrast, the SCAPIS cohort is relatively young 
(median, 57.4±4.3 years) and most of the coronary ath-
erosclerosis identified by CCTA was mild. It is therefore 
possible that the progression from early coronary athero-
sclerosis to acute coronary events will take >10 years. 
Nevertheless, the high prevalence of subclinical coronary 
atherosclerosis raises the question as to whether CCTA 
could help identify persons more precisely who would 
benefit from the early initiation of preventative therapies 
to treat the underlying atherosclerotic disease process 
and reduce their lifetime risk of coronary events.
Long-term follow-up of the SCAPIS cohort will inform 
whether measures of coronary atherosclerosis are supe-
rior to risk score estimates with or without CAC testing 
for the prediction of coronary events. Future analyses 
should evaluate alternative measures of coronary athero-
sclerosis burden including functional measurements of 
stenosis severity and quantification of plaque character-
istics that have been shown to identify those at high risk 
in those with symptoms.15 CCTA is not uniformly avail-
able in all health care systems, and, even where testing 
is routinely performed, a significant expansion in capac-
ity would be needed to establish high-risk population 
screening programs. In this context, the SCAPIS inves-
tigators should explore the potential for novel blood and 
imaging biomarkers to identify those persons who are 
most likely to have subclinical coronary atherosclerosis.
Evidence from randomized controlled trials will ultimately 
be needed to determine whether targeting preventative 
therapy using CCTA is superior to our current practice of 
estimating risk using probabilistic risk scores. This ques-
tion is currently being addressed in individuals with ≥1 
cardiovascular risk factors enrolled in the SCOT-HEART 
2 trial (Computed Tomography Coronary Angiography for 
the Prevention of Myocardial Infarction; URL: http://www.
clinicaltrials.gov. Unique identifier: NCT03920176), which 
will determine whether screening with CCTA is associated 
with a reduction in the rate of fatal or nonfatal myocar-
dial infarction in comparison with a risk score approach. 
In the meantime, the search for novel bioimaging markers 
of coronary atherosclerosis continues, and the SCAPIS 
investigators are well placed to lead these discoveries and 
to design novel approaches that may reduce the burden of 
coronary heart disease on our communities.
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